Product Introduction Copy (Marketing Copy)
ZFirst Myocardial Tri-Test Kit: Quantum Dot Technology, Racing Against "Golden 15 Minutes" for Life
The combined detection of cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), and myoglobin is the gold standard for assisting in the diagnosis of acute myocardial infarction (AMI). ZFirst employs the innovative quantum dot immunofluorescence method (QD-FIA) to achieve simultaneous and precise quantitative detection of the three indicators on a single test card, providing decisive support for early assessment and risk stratification of chest pain in clinical settings. 

Core Advantages (Product Highlights)
Trinity, efficient screening. With just one sample addition, quantitative results for cTnI, CK-MB and Myo can be obtained simultaneously. It covers the early (Myo), mid-stage (CK-MB) and highly specific period (cTnI) indicators of myocardial injury, effectively avoiding the "blind period" of single-item detection.
Quantum Dot Tech's ultimate sensitivity (Quantum Dot Tech) utilizes the physical characteristics of quantum dots, such as narrow emission and extremely strong light stability. Its detection limit is far superior to that of ordinary fluorescent reagents. This is crucial for indicators like cTnI, which require capturing extremely minute damage signals, enabling earlier detection of myocardial damage.
POCT ultra-fast reporting. Compatible with the ZFirst fluorescence analyzer, the detection process is extremely simple, and a full quantitative report can be produced in 10-15 minutes. This helps chest pain centers meet the "time-critical" emergency needs.
Outstanding system stability. Quantum Dot technology can effectively shield the interference of background fluorescence in blood samples, ensuring excellent consistency in serum, plasma or whole blood samples.
25-person professional packaging. Each individual package is independently sealed, and an ID chip is used for automatic calibration of batch information. This not only reduces the cost of a single test but also eliminates the error of manual standardization, making it suitable for emergency departments and ICUs of various sizes.

Product Specifications

Product Summary

The ZFirst Cardiac Marker Trio Test Kit by Beijing Jiachuang Jiuhe Global Trade Co., Ltd utilizes advanced Quantum Dot Fluorescence Immunoassay (QD-FIA) technology to provide rapid, fully quantitative detection of Cardiac Troponin I (cTnI), Creatine Kinase-MB (CK-MB), and Myoglobin (Myo) on a single cassette. Designed for emergency care and chest pain centers, this cTnI CK-MB Myo Combo Test delivers precise results in 10 to 15 minutes from serum, plasma, or whole blood samples. By capturing micro-level signals of myocardial injury early, this POCT Cardiac Troponin I Kit supports clinicians in making critical decisions during time-sensitive cardiac emergencies.

Detailed Product Overview

In emergency medicine, particularly regarding acute coronary syndrome (ACS) and Acute Myocardial Infarction (AMI), early diagnosis directly correlates with patient survival rates. The ZFirst Cardiac Marker Trio Test Kit by Beijing Jiachuang Jiuhe Global Trade Co., Ltd addresses this critical need by combining three essential biomarkers into one streamlined testing process.

The pathophysiology of myocardial injury follows a distinct temporal pattern:

1. Myoglobin (Myo): Released within 1 to 2 hours after the onset of myocardial injury, serving as an ultra-early marker.

2. Creatine Kinase-MB (CK-MB): Rises within 3 to 8 hours, offering crucial insight into mid-stage injury progression and re-infarction monitoring.

3. Cardiac Troponin I (cTnI): Elevates within 3 to 6 hours and remains elevated for up to 10 to 14 days, providing high specificity as the definitive marker for cardiac necrosis.

Single-marker assays often suffer from diagnostic "blind spots" due to these varying release kinetics. The ZFirst Cardiac Marker Trio Test Kit resolves this limitation by delivering simultaneous quantification of all three markers. Utilizing state-of-the-art Quantum Dot Fluorescence Immunoassay technology, this Acute Myocardial Infarction Diagnostic Kit provides exceptional analytical sensitivity, allowing emergency medical teams to assess risk profiles and initiate life-saving treatments rapidly.

Key Product Features

• Three-in-One Comprehensive Screening: Single sample application provides simultaneous quantitative results for cTnI, CK-MB, and Myoglobin, eliminating individual test delays.

• Rapid Turnaround Time: Delivers complete quantitative diagnostic reports in 10–15 minutes using compatible ZFirst fluorescence analyzers.

• Broad Matrix Compatibility: Supports whole blood, serum, and plasma, reducing sample processing time in urgent point-of-care environments.

• Smart ID Chip Calibration: Each box includes an ID chip for automatic lot-specific calibration, reducing human error and workflow complexity.

• Hygienic Single-Test Packaging: Individually sealed test cassettes preserve reagent stability across an 18-month shelf life.

Technical Advantages & Technology Deep-Dive

The Power of Quantum Dot Fluorescence Immunoassay (QD-FIA)

Traditional immunochromatographic assays and basic fluorescent reagents often struggle with background interference and lower sensitivity. The ZFirst Cardiac Marker Trio Test Kit leverages quantum dots—nanometer-scale semiconductor crystals that exhibit unique physical and optical properties:

• Narrow Emission & High Quantum Yield: Quantum dots produce sharp, intense fluorescence signals, enabling the POCT Cardiac Troponin I Kit to achieve significantly lower detection limits compared to conventional fluorophores.

• Exceptional Photostability: Unlike organic dyes that degrade under exposure to light, quantum dots resist photobleaching, ensuring reliable signal reading and reproducible analytical results.

• Background Interference Reduction: The extended fluorescence lifetime of quantum dots allows for time-resolved measurement, effectively eliminating autofluorescence signals from complex blood components.

Product Specifications

Clinical Applications

The ZFirst Cardiac Marker Trio Test Kit is engineered for high-demand healthcare environments requiring rapid diagnostic output:

1. Chest Pain Centers: Rapidly stratify patients presenting with acute chest pain, reducing door-to-balloon time.

2. Emergency Departments (ED): Serve as a reliable primary tool for evaluating suspected acute myocardial infarction.

3. Intensive Care Units (ICU): Enable continuous, quantitative monitoring of myocardial damage progression in critically ill patients.

4. Cardiology Outpatient Clinics: Support routine evaluations and follow-ups for high-risk cardiovascular patients.

Business Value & Commercial Benefits for B2B Partners

Partnering with Beijing Jiachuang Jiuhe Global Trade Co., Ltd for the distribution of the ZFirst Cardiac Marker Trio Test Kit brings substantial operational and commercial advantages to healthcare providers and medical distributors:

• Cost-Efficiency: Combining three critical parameters into a single cassette lowers cost-per-test metrics, reduces plastic waste, and minimizes reagent storage space.

• Enhanced Hospital Throughput: Fast reaction times improve emergency room triage efficiency, reducing patient stays and lowering hospital operating overhead.

• Flexible Storage Conditions: Storable at ambient temperatures (2°C to 30°C), this kit reduces cold-chain shipping costs and simplifies inventory management.

• Competitive B2B Positioning: Distributor partners gain access to cutting-edge Quantum Dot Fluorescence Immunoassay products, establishing a strong competitive presence in POCT markets.

Frequently Asked Questions (FAQ)

Q1: How does the cTnI CK-MB Myo Combo Test improve diagnostic accuracy over single-item tests?

A1: Myoglobin rises early (1–2 hours), CK-MB offers mid-stage monitoring, and cTnI provides high cardiac specificity. Evaluating all three simultaneously with the cTnI CK-MB Myo Combo Test prevents diagnostic delays caused by varying marker elevation timelines.

Q2: What is the primary operational advantage of Quantum Dot technology in this Acute Myocardial Infarction Diagnostic Kit?

A2: Quantum Dot Fluorescence Immunoassay provides superior photostability, higher signal intensity, and minimal interference from whole blood matrices, yielding superior sensitivity for early biomarker detection.

Q3: Can the ZFirst Cardiac Marker Trio Test Kit be used with non-centrifuged blood samples?

A3: Yes. The ZFirst Cardiac Marker Trio Test Kit by Beijing Jiachuang Jiuhe Global Trade Co., Ltd is validated for whole blood, serum, and plasma, allowing immediate testing without plasma separation steps.